Indication
Thymoma, Type B3
2 clinical trials
1 product
2 drugs
Clinical trial
Single-arm, Multicentre, Phase II Study of Immunotherapy in Patients With Type B3 Thymoma and Thymic Carcinoma Previously Treated With ChemotherapyStatus: Active (not recruiting), Estimated PCD: 2023-12-01
Drug
T-VECClinical trial
A Multicentric, Open-Label, Single Arm Phase II Study To Evaluate The Efficacy And Safety Of The Combination Of PEmbrolizumab And Lenvatinib In Pre-Treated Thymic Carcinoma PaTIents. PECATI.Status: Active (not recruiting), Estimated PCD: 2024-06-30
Drug
mFOLFOX6Product
Lenvatinib